C2N Diagnostics

We’re getting ready for the 2024 NAMCP Medical Directors Institute Fall Managed Care Forum from Nov. 7-8. This is a terrific opportunity for C2N to share details about the Precivity™ tests, which are innovative new blood tests intended for use in patients 55 and older with signs or symptoms of mild cognitive impairment or dementia. These tests aid healthcare providers in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease, and inform medical management and treatment decisions. The Managed Care Forums are a joint creation of the American Association of Integrated Healthcare Delivery Systems (AAIHDS), the American Association of Managed Care Nurses (AAMCN) and the NAMCP Medical Directors Institute. https://lnkd.in/d2EM8SK #NAMCP #bloodtests #managedcare #precisionmedicine #Alzherimersdisease #dementia #FallManagedCareForum

At C2N, our team members are proud to go the extra mile to help in the race against Alzheimer’s disease — and they take that comment literally! Our colleague Brianne Peters took part in the New York City Marathon this weekend. Brianne chose to join the Alzheimer's Association® team and help raise funds for a great cause while training for the race. She was one of the top individual fundraising participants for the Alzheimer’s Association team. Thank you Brianne for your support of individuals living with cognitive impairment. #alzheimersassociation #nycmarathon #alzheimers #biomarkers #Alzheimersdiagnostics

The Washington Post health reporter Laurie McGinley recently answered online questions about the progress occurring in diagnosing and treating Alzheimer’s disease. Click to read her initial reporting on research involving the C2N’s Precivity™ line of blood tests that help healthcare providers diagnose Alzheimer’s disease; the research found the PrecivityAD2 test delivered a highly statistically significant accuracy of over 90% at a pre-defined, single binary cutoff compared to cerebrospinal fluid (CSF) analysis or amyloid PET analysis. https://archive.ph/QkSaI Click to read her answer discussing the accuracy of blood tests to aid in Alzheimer’s disease diagnosis (scroll to question 10). https://archive.ph/xLjQ6 #WashingtonPost #Alzheimers #Alzheimersdisease #precisiomedicine #bloodtests

Dr. Sheena Aurora, Vice President of Neurology of #C2N Diagnostics, presents at today’s CTAD Late Breaking Roundtable on Plasma p-tau217 assays in clinical practice: Current uses and future considerations for diagnosing Alzheimer’s disease. #CTAD #ClinicalTrialsforAlzheimersDisease #CTAD2024

Joel Braunstein, MD, CEO of #C2N Diagnostics, presents ground-breaking clinical utility data on the PrecivityAD2™ test in his CTAD session titled “An evaluation of the impact of a multi-analyte blood biomarker test for evaluating cognitive impairment: Results of the QUIP II clinical utility study. (Publication in review.) #CTAD #ClinicalTrialsforAlzheimersDisease #CTAD2024

See our graphics and calendar below for details about C2N-related sessions on Friday, November 1 at CTAD: 9:00 a.m. – 9:15 a.m. CEST LB22: Timing of changes in Alzheimer’s disease plasma biomarkers using amyloid and tau PET clocks Poster session: Friday, November 1 – 7:15 a.m. – 5:00 p.m. CEST P199 Sequential Administration of Digital Testing to Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis of Alzheimer’s Disease in AdventHealth   P200 Clinical Management during the Davos Alzheimer’s Collaborative Early Detection of Cognitive Impairment Program in Six Countries #CTAD #ClinicalTrialsforAlzheimersDisease #CTAD2024

We’re getting ready for another important day at CTAD—researchers and clinicians have important new data to share about the Precivity™ line of blood tests. Madrid Marriott Auditorium Hotel & Convention Center is the location. Thursday, October 31 8:30 a.m. – 8:45 a.m. CEST LB7: Plasma p-tau217 and related CSF proteomic markers of pathological progression are slowed by p75NTR modulation: A Phase 2a trial of LM11A31 in Alzheimer’s disease 1:55 p.m. – 2:20 p.m. CEST Keynote 4: Fluid biomarkers in research, clinical trials, and clinical practice Poster session: Thursday October 31 – 7:15 a.m. to Friday, November 1 – 5:00 p.m CEST LP054 Biomarker Evaluation in Young Onset Dementia from Diverse Populations (BEYONDD)   P072 Diagnostic Performance of Plasma Alzheimer’s Disease Biomarkers for Predicting Amyloid/Tau/Neurodegeneration Let’s connect in person. Schedule a meeting with our team at this link: https://lnkd.in/gVMKRD4r #CTAD #ClinicalTrialsforAlzheimersDisease #CTAD2024

C2N’s sessions at CTAD continue to attract attention as researchers share their latest findings about the Precivity™ line of blood tests. We encourage you to click this link to schedule a meeting with our team. https://lnkd.in/gVMKRD4r   All sessions and posters will be held at the Madrid Marriott Auditorium Hotel & Convention Center. Wednesday, October 30 5:25 p.m. – 5:40 p.m. CEST 0C18 – Blood biomarkers to detect Alzheimer’s disease in clinical practice — a cross-sectional study in primary and secondary care Poster session: Tuesday, October 29 – 3:00 p.m. to Wednesday, October 30 – 5:00 p.m. CEST P007 Using plasma pTau217 ratio to forecast longitudinal progression substantially increases the efficiency of AD clinical trials #CTAD #ClinicalTrialsforAlzheimersDisease #CTAD2024

C2N continues to set a standard in innovation in Alzheimer’s disease diagnostics through numerous presentations by esteemed researchers and clinicians at CTAD. Join us in Madrid and be among the first to learn about exciting new data for the Precivity™ line of blood tests. We encourage you to click this link to schedule a meeting with our team. https://lnkd.in/gVMKRD4r   All sessions and posters will be held at the Madrid Marriott Auditorium Hotel & Convention Center. Eight sessions and five posters will offer novel insights relating to the Precivity™ blood tests. These presentations/posters include: Sessions on C2N's Test Data Tuesday, October 29 5:40 p.m. – 5:55 p.m. CEST 0C4 - Anti-tau therapeutic antibody, E2814, reduces early and late tau pathology biomarkers in patients with DIAD 6:10 p.m. – 6:50 p.m. CEST Late breaking Symposium 1 - The AHEAD 3-45 Study: Design and Results of a Novel Screening Process for a Preclinical AD Trial Poster session: Tuesday, October 29 – 3:00 p.m. to Wednesday, October 30 – 5:00 p.m. CEST P007 Using plasma pTau217 ratio to forecast longitudinal progression substantially increases the efficiency of AD clinical trials #CTAD #ClinicalTrialsforAlzheimersDisease #CTAD2024

Joel Braunstein, MD, CEO of #C2N Diagnostics, presents at today’s ADDF Summit at CTAD on the Future of Alzheimer’s Biomarkers in Clinical Care and Research with other research luminaries Dr. Miia Kivipelto, Dr. Jeffrey Cummings, Dr. Suzanne Schindler, Dr. Charlotte Teunissen, Dr. Henrik Zetterberg, and Howard Fillit, MD. #Alzheimers #Alzheimersdisease #precisiomedicine #bloodtests #CTAD24 #ADDFSummit #biomarkers